{"entity":{"id":"nct07383116","kind":"trial","name":"Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous No","aka":[],"tldr":"A phase 3 trial of pemetrexed, carboplatin, cisplatin and tislelizumab in lung cancer, run by Shanghai Huaota Biopharmaceutical Co., Ltd., not yet recruiting.","summary":"Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer is a phase 3, randomised interventional study registered as NCT07383116 by Shanghai Huaota Biopharmaceutical Co., Ltd., with a registry enrolment figure of 500 participants, started 2026-01-15 and due to reach its primary completion in 2028-04-10. Interventions recorded: Pemetrexed injection; Carboplatin Injection; Cisplatin injection; HB0025 Injection; Tislelizumab. Conditions listed: Non Squamous Non-small Cell Lung Cancer. Primary outcome: Progression-free survival (PFS). Lung eligibility wording from the registry: \"Histologically or cytologically confirmed locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV) non-squamous non-small cell lung cancer (NSCLC) (confirmed per the 9th Edition of the TNM Staging System for Lung Cancer by the Union for International Cancer Control \\[UICC\\] and the American Joint\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07383116","url":"https://clinicaltrials.gov/study/NCT07383116"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["pemetrexed","carboplatin","cisplatin","tislelizumab"],"companies":["huabo-biopharm"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07383116","phase":"3","setting":"A Randomized, Double-Blind, Multicenter Phase III Clinical Study of HB0025 Injection Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer","sponsor":"Shanghai Huaota Biopharmaceutical Co., Ltd.","enrolled":500,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07383116/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"},{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/"}],"company":[{"id":"huabo-biopharm","kind":"company","name":"Huabo Biopharm","route":"/companies/huabo-biopharm/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}